‘Great buzz' at Irish shop which sold EuroMillions jackpot-winning ticket
The Irish shop which sold the winning EuroMillions ticket is going to have a 'big celebration', its owner has said.
Clifford's Centra on Shandon Street in Cork city has been announced as the shop which sold the 250 million euro jackpot-winning ticket.
Owner Ted Clifford said the news is 'very exciting'.
With sweltering temperatures across Ireland on Friday, he said: 'It is definitely going to be the hottest day of the year at Shandon Street.'
Mr Clifford, who was informed of the win on Thursday evening, initially believed it was a 'wind up'.
However, he said it is not the first time the shop has sold a big-prize ticket.
'It is fantastic news – this all kicked off on New Year's Eve when we sold a 100,000 euro ticket to a local person.
'That's when our luck, or winning streak, started.'
📞🤩 The moment Clifford's Centra, Shandon Street, Cork City, found out their shop sold the winning #EuroMillions ticket of €250 MILLION! #ItCouldBeYou
18+ Play Responsibly Play for Fun pic.twitter.com/7e2gAIt3J5
— The Irish National Lottery (@NationalLottery) June 20, 2025
Mr Clifford, who is the third generation owner of the store which has been operating for 95 years, said he is 'proud to be part of the community'.
Speaking on RTE radio's Morning Ireland, he sent his 'warmest congratulations' to the winner and their family.
Asked if he knows who that might be, he replied: 'I have no idea, it's a busy shop – there's a lot of people in and out.
'Hopefully they will have good fortune with their money.'
Mr Clifford said it is a 'life-changing amount of money', but the National Lottery will support the winner.
He said he will use 25,000 euro in prize money for the shop to have a 'big celebration' with the staff.
He said there was a 'great buzz' and 'a lot of people around' following the announcement.
The winner of the jackpot has already contacted the National Lottery.
It is the 18th Irish winner and the largest ever Irish win of the EuroMillions jackpot.
The winning numbers from Tuesday's draw were 13, 22, 23, 44 and 49, with lucky stars 3 and 5.
Irish National Lottery chief executive Cian Murphy had urged the winner earlier in the week to 'stay calm' as the 'massive' win could come as a shock.
The EuroMillions jackpot is capped once it reaches 250 million euro – or £208 million on current currency conversions.
This jackpot reached the maximum amount on Friday June 6 after rolling over several times.
In total, more than 92,000 players in Ireland won prizes in the EuroMillions and Plus games.
The last Irish winner of the EuroMillions jackpot was in February 2022, when a person won 30.9 million euro with a quick pick ticket they purchased at a service station in Ballina, Co Tipperary.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Bishop Fleming secures minority investment from Synova
Private equity firm Synova has picked a minority stake in Bishop Fleming to back the next growth phase of the UK-based accountancy business. This investment from Synova, which oversees more than £1.7bn ($2.28bn) in capital in UK, Ireland and Continental European markets, will speed up Bishop Fleming's growth plan, a statement from the accountancy firm revealed. It is aimed at positioning Bishop Fleming among the 'leading' national accountancy firms in the UK, the statement added. The deal awaits regulatory approval. The accountancy firm's Better Growth strategy outlines a future of 'sustainable' growth, with the expansion expected to introduce new capabilities, specialist expertise, and talent. Bishop Fleming managing partner Andrew Sandiford said: 'We launched our Better Growth business strategy two and half years ago, designed to double the size of our business through sustainable organic growth. Our performance during that time has been unrivalled in the mid-market space, such that we are now extending that Better Growth vision to grow beyond £200m and over 2,000 people.' 'This investment is the next logical step to develop Bishop Fleming on the national stage through strategic planned M&A activity.' Sandiford added: 'We are delighted to select Synova as an investment partner to our business. We believe they deliver the best of both worlds. Uniquely enabling us to remain majority partner-owned and led, maintaining control of our business through a traditional partnership business model, but with the exciting backing of a minority investment that perfectly aligns and accelerates our business growth plans.' Bishop Fleming said it is only the second accountancy firm to deploy the full Workday ERP platform, an investment considered pivotal for scaling up the business. The firm, which reported a 15% fee growth to over £48m in 2025, runs nine offices across the South-West of England and West Midlands. Recent milestones in Bishop Fleming's growth include the launch of a new office in Birmingham at the start of 2025, expanding its presence in The Midlands. The firm also expanded its Bristol office and relocated its Exeter office to Winslade Park. Guidance for the transaction was provided by Alantra, a global financial services firm, with additional advisory from PwC, Strategy&, and Addleshaw Goddard. "Bishop Fleming secures minority investment from Synova" was originally created and published by International Accounting Bulletin, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Yahoo
6 hours ago
- Yahoo
Human Papillomavirus (HPV) Vaccines Strategic Business Research Report 2024-2025 & 2030 - Rising Global Awareness of HPV-Linked Cervical and Oropharyngeal Cancers Drives Preventive Vaccination Uptake
The global Human Papillomavirus (HPV) Vaccines market, valued at USD 5.5 billion in 2024, is anticipated to grow to USD 9.7 billion by 2030 at a CAGR of 9.9%. This report offers comprehensive analysis of market trends and growth drivers, providing vital insights for businesses. Key highlights include the evolution of vaccine formulations, such as nonavalent vaccines targeting multiple HPV strains, which are crucial in preventing HPV-related cancers globally. Strategic vaccination programs and improved distribution strategies are driving market expansion, particularly in emerging economies. Despite barriers like misinformation and hesitancy, increased public awareness and partnerships with organizations like Gavi are expected to enhance uptake, especially in high-burden regions. The report also assesses the impact of global tariff developments on the HPV vaccines market. Human Papillomavirus (HPV) Vaccines Market Dublin, June 19, 2025 (GLOBE NEWSWIRE) -- The "Human Papillomavirus (HPV) Vaccines - Global Strategic Business Report" report has been added to global market for Human Papillomavirus (HPV) Vaccines was estimated at US$5.5 Billion in 2024 and is projected to reach US$9.7 Billion by 2030, growing at a CAGR of 9.9% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Human Papillomavirus (HPV) Vaccines market. Human papillomavirus (HPV) vaccines play a central role in the prevention of HPV-related cancers, including cervical, oropharyngeal, anal, and genital cancers. With over 200 types of HPV identified and high-risk strains such as HPV-16 and HPV-18 accounting for the majority of cervical cancer cases, widespread immunization is viewed as a cornerstone of global cancer prevention strategies. These vaccines stimulate the immune system to develop antibodies against targeted viral strains, offering long-term protection against persistent infections and precancerous lesions. The Growth in the HPV Vaccines Market Is Driven by Several is driven by increasing global efforts to prevent HPV-related cancers, expansion of immunization programs, and the availability of broad-spectrum vaccine formulations. Rising public health investment in women's health and cancer prevention, along with WHO's cervical cancer elimination strategy, is catalyzing demand. The inclusion of boys in vaccination programs and growing incidence of HPV-linked head and neck cancers are further expanding the addressable progress in vaccine efficacy, long-term protection data, and potential single-dose regimens is supporting broader implementation. Additionally, partnerships between governments, vaccine developers, and health organizations are enhancing procurement, education, and infrastructure especially in emerging markets. Digital health platforms and mHealth campaigns are also improving outreach and record tracking, increasing vaccine uptake. Collectively, these trends are reinforcing HPV vaccines as a critical tool in global disease prevention and a dynamic segment within the broader vaccines Are Vaccine Formulations and Distribution Strategies Evolving?HPV vaccines have progressed from bivalent formulations (targeting HPV-16 and 18) to quadrivalent (adding protection against HPV-6 and 11) and now to nonavalent vaccines, which protect against nine HPV strains, including those responsible for up to 90% of cervical cancers. These broader-spectrum vaccines offer greater coverage and are expected to dominate future procurement and immunization programs. Continuous innovation in recombinant vaccine production and adjuvant systems is enhancing immune response and duration of is being optimized through school-based vaccination programs, gender-neutral campaigns, and integration with national childhood immunization schedules. Advances in cold-chain infrastructure, coupled with partnerships between governments, NGOs, and vaccine manufacturers, are improving access in low- and middle-income countries. Single-dose regimens are also under investigation as a cost-effective and logistically simpler alternative, with promising results that may reshape vaccination protocol and broaden global Is Uptake Increasing and What Barriers Remain?Vaccination uptake is rising in North America, Europe, and parts of Asia-Pacific where public awareness, healthcare infrastructure, and policy support are strong. Gender-neutral vaccination strategies are gaining traction, particularly in countries prioritizing the prevention of head and neck cancers linked to HPV in males. Latin America and Sub-Saharan Africa, despite high HPV burden, still face challenges including supply limitations, healthcare access gaps, and cultural include misinformation, vaccine hesitancy, and inconsistent public health messaging, particularly in conservative or resource-constrained regions. Limited adult vaccination programs and affordability issues also hamper broader market penetration. However, partnerships with organizations such as Gavi, the Vaccine Alliance, are actively addressing supply inequities and financial barriers through tiered pricing and donor-funded initiatives. As these issues are mitigated, market growth is expected to accelerate, particularly in high-burden Insights: Market Growth: Understand the significant growth trajectory of the Tetravalent segment, which is expected to reach US$5.8 Billion by 2030 with a CAGR of a 9.5%. The Nonavalent segment is also set to grow at 11.3% CAGR over the analysis period. Regional Analysis: Gain insights into the U.S. market, valued at $1.5 Billion in 2024, and China, forecasted to grow at an impressive 13.4% CAGR to reach $2.0 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific. Report Features: Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030. In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa. Company Profiles: Coverage of players such as Barinthus Biotherapeutics, Bharat Biotech, BioNTech SE, CanSino Biologics Inc., and more. Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments. This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include: Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs. Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015. Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends. Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape. Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players. Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities. Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage. Key Attributes: Report Attribute Details No. of Pages 279 Forecast Period 2024 - 2030 Estimated Market Value (USD) in 2024 $5.5 Billion Forecasted Market Value (USD) by 2030 $9.7 Billion Compound Annual Growth Rate 9.9% Regions Covered Global MARKET OVERVIEW Influencer Market Insights World Market Trajectories Tariff Impact on Global Supply Chain Patterns Human Papillomavirus (HPV) Vaccines - Global Key Competitors Percentage Market Share in 2025 (E) Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E) MARKET TRENDS & DRIVERS Rising Global Awareness of HPV-Linked Cervical and Oropharyngeal Cancers Drives Preventive Vaccination Uptake Inclusion of HPV Vaccines in National Immunization Programs Expands Coverage Across Adolescents and Young Adults WHO and GAVI Support for HPV Vaccine Rollout in Low-Income Countries Strengthens Public Health Impact Expansion of Gender-Neutral Vaccination Policies Fuels Demand Across Male and Female Populations Technological Advancements in Vaccine Formulations Improve Long-Term Efficacy and Broaden Strain Coverage Increased School-Based Immunization Drives High Compliance Rates in Developed and Emerging Regions Public-Private Partnerships and Awareness Campaigns Boost Community-Level Vaccine Acceptance Improved Cold Chain Infrastructure and Global Procurement Facilitate Distribution to Remote Areas Rising Incidence of HPV-Associated Head and Neck Cancers Spurs Broader Advocacy for Adult Vaccination Growing Market Entry of Biosimilar and Region-Specific HPV Vaccines Enhances Accessibility and Affordability FOCUS ON SELECT PLAYERS Barinthus Biotherapeutics Bharat Biotech BioNTech SE CanSino Biologics Inc. GlaxoSmithKline plc Inovio Pharmaceuticals Johnson & Johnson Merck & Co., Inc. Moderna, Inc. Novavax, Inc. Pfizer Inc. Sanofi S.A. Serum Institute of India Sinovac Biotech Ltd. Takeda Pharmaceutical Company Valneva SE Vaxart, Inc. Walvax Biotechnology Co., Ltd. Wantai BioPharm Xiamen Innovax Biotech Co., Ltd. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Human Papillomavirus (HPV) Vaccines Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Modern Architecture Drives ETFE Membrane Popularity with Focus on Lightweight and Aesthetic Structures
Discover the growing potential of the ETFE Architectural Membrane Market, projected to hit USD 1.21 billion by 2032. With a CAGR of 8.8%, the demand for lightweight, durable, and eco-friendly materials is rising. Key applications include stadiums, airports, and more, driven by green building trends globally. ETFE Architectural Membrane Market Dublin, June 20, 2025 (GLOBE NEWSWIRE) -- The "ETFE Architectural Membrane Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges" has been added to offering. The Global ETFE Architectural Membrane Market is poised for substantial growth, with a projected market size value of USD 677 million in 2025. Forecasts predict worldwide sales will reach USD 1.21 billion by 2032, marking a robust CAGR of 8.8%. This growth trajectory is fueled by the increasing demand for ETFE (Ethylene Tetrafluoroethylene) membranes, which are being favored in modern architecture for their blend of aesthetic and environmental benefits. ETFE membranes are appreciated for their exceptional strength-to-weight ratio, UV resistance, high translucency, and self-cleaning properties, making them ideal for use in roofing systems, facades, skylights, and atriums across varied structures such as stadiums, transportation terminals, greenhouses, and commercial centers. These membranes outperform traditional glass and polycarbonate in thermal insulation and flexibility, offering an environmentally friendly alternative with low recyclability impact, which complements sustainable construction efforts. The market has seen increased interest in ETFE structures, mainly due to rising investments in sports and public infrastructure projects as global events spur urban redevelopment. Innovations in multi-layer ETFE cushion systems, along with advancements in air inflation and shading mechanisms, have broadened design possibilities for energy-efficient enclosures. Digital advancements in construction, including 3D modeling, BIM, and parametric design, facilitate customization of ETFE applications for complex geometries. The adoption of ETFE is notably growing in Asia-Pacific and the Middle East due to its resilience in extreme climates and cost-effective maintenance. The push towards net-zero carbon construction further encourages the integration of high-performance membrane materials like ETFE in project designs. Expected advancements in smart coatings, integrated photovoltaics, and intelligent shading systems will enhance ETFE's role in sustainable architecture, offering functionality and design flexibility. Key Takeaways - ETFE Architectural Membrane Market: Increasing global demand for lightweight, durable, and aesthetic building materials pushes ETFE membranes into mainstream architectural design. Major adopters include stadiums, airports, and exhibition centers due to ETFE's ability to cover expansive areas with minimal structural weight. Architectural preferences for transparency, daylight optimization, and organic shapes match well with ETFE's properties. Temperature-sensitive environments benefit from ETFE's thermal insulation capabilities and climate adaptability. Asia-Pacific, driven by infrastructure projects in China, India, and Southeast Asia, is emerging as a critical growth region. Growing emphasis on green certifications and ESG goals promote recyclable materials like ETFE. Technological innovations such as 3D modeling and digital fabrication promise efficient custom ETFE structure designs. A global shift to replace aging roofs with ETFE offers opportunities for retrofits, especially in Europe and North America. The integration of solar panels and dynamic shading transforms ETFE systems into energy-generating components. Smart membrane technologies with sensors and responsive controls are under development, facilitating adaptive architecture. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $677 Million Forecasted Market Value (USD) by 2034 $1446 Million Compound Annual Growth Rate 8.8% Regions Covered Global Companies Featured Vector Foiltec Taiyo Kogyo Corporation Birdair Inc. SEFAR AG Tensile Structure Systems Nowofol Kunststoffprodukte GmbH & Co. KG Hightex GmbH Serge Ferrari Group MakMax Group Cowley International Group Novum Structures LLC Georg + Otto Friedrich GmbH Covertex Membranes International Shanghai Taiyo Kogyo Co., Ltd. Frei Otto Structures For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment ETFE Architectural Membrane Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
